Investigational Drug Information for LIK066

What is the drug development status for LIK066?

LIK066 is an investigational drug.

There have been 12 clinical trials for LIK066. The most recent clinical trial was a Phase 2 trial, which was initiated on June 5^th 2015.

The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Non-alcoholic Fatty Liver Disease. The leading clinical trial sponsors are Novartis Pharmaceuticals and [disabled in preview].

There are six US patents protecting this investigational drug and eighty-one international patents.

Summary for LIK066

US Patents	6
International Patents	81
US Patent Applications	26
WIPO Patent Applications	34
Japanese Patent Applications	6
Clinical Trial Progress	Phase 2 (2015-06-05)
Vendors	13

Recent Clinical Trials for LIK066

Title	Sponsor	Phase
Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.	Novartis Pharmaceuticals	Phase 2
A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With Obesity	Novartis Pharmaceuticals	Phase 2
Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients	Novartis Pharmaceuticals	Phase 2

See all LIK066 clinical trials

Clinical Trial Summary for LIK066

Top disease conditions for LIK066

Top clinical trial sponsors for LIK066

See all LIK066 clinical trials

US Patents for LIK066

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
LIK066		C-aryl glucoside derivative, preparation methods thereof, and medical applications thereof	YOUNGENE THERAPEUTICS CO., LTD (China (Shanghai) Pilot Free Trade Zone, CN)
LIK066		Glycoside derivatives and uses thereof	Novartis AG (Basel, CH)
LIK066		Glycoside derivatives and uses thereof	Novartis AG (Basel, CH)
LIK066		Glycoside derivatives and uses thereof	Novartis AG (Basel, CH)
LIK066		Glycoside derivatives and uses thereof	Novartis AG (Basel, CH)
LIK066		Glycoside derivatives and uses thereof	Novartis AG (Basel, CH)

International Patents for LIK066

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
LIK066	Australia	AU2014317663	2033-09-09
LIK066	Canada	CA2923522	2033-09-09
LIK066	China	CN105518014	2033-09-09
LIK066	China	CN107311992	2033-09-09
LIK066	European Patent Office	EP3056507	2033-09-09
LIK066	Spain	ES2828548	2033-09-09